Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression
Open accessThe DOI matches its Crossref record; 205 of the 210 references it cites were found in a registry or an index.
Abstract
Approximately 90% of pancreatic cancers are pancreatic ductal adenocarcinomas (PDAC). PDAC is the fourth leading cause of cancer death world-wide. Therapies for PDAC are largely ineffective due to the dense desmoplastic tumor microenvironment which prevents chemotherapeutic drugs and small molecule inhibitors from exerting effective anti-cancer effects. In this review, we will discuss the roles of TP53 and miRs on the PDAC tumor microenvironment and how loss of the normal functions of TP53 promote tumor progression. The TP53 gene is mutated in approximately 50% of pancreatic cancers. Often, these TP53 mutations are point mutations which confer additional functions for the TP53 proteins. These are called gain of function (GOF) mutations (mut). Another class of TP53 mutations are deletions which result in loss of the TP53 protein; these are referred to TP53-null mutations. We have organized this review into various components/properties of the PDAC microenvironment and how they may be altered in the presence of mutant TP53 and loss of certain miR expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TP53 mutations, found in 50–90% of pancreatic ductal adenocarcinomas, significantly affect carcinogenesis, prognosis and treatment response [17,21,34,35].”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [34]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These mutations, particularly gain-of-function (GOF) variants, alter the tumor microenvironment, promoting proliferation and chemotherapy resistance [34,36].”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [34]
The cited source says what the claim attributes to it.
In the citing paper
“TP53’s multifaceted role extends to metabolic regulation, shaping the hostile PDAC microenvironment by influencing metabolic reprogramming, autophagy and ferroptosis [34].”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [34]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Huang, F., Chen, W., Peng, J., Li, Y., Zhuang, Y., Zhu, Z., Shao, C., Yang, W., Yao, H., & Zhang, S. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0845-6 · Cited by 134 · cited 2×
“Various miRs and LncRNAs are involved in the regulation of autophagy; these include miR-506 [145], miR-372 [146] and LncRNA PVT1 [147].”
BackgroundRetractedNF-κB, inflammation, immunity and cancer: coming of age
Taniguchi, K., & Karin, M. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.142 · Cited by 2,679 · cited 1×
“Increased IL-6 expression is associated with metastasis [12].”
BackgroundDistinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer
Öhlund, D., Handly-Santana, A., Biffi, G., Elyada, E., Almeida, A. S., Ponz-Sarvise, M., Corbo, V., Oni, T. E., Hearn, S. A., Lee, E. J., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20162024 · Cited by 2,590
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
(1999) · PubMed · Cited by 2,204
Mendel, D. B., Laird, A., Xin, X., Louie, S. G., Christensen, J. G., Li, G., Schreck, R., Abrams, T. J., Ngai, T. J., Lee, L. B., et al. (2003) · PubMed · Cited by 2,157
YAP/TAZ at the Roots of Cancer
Zanconato, F., Cordenonsi, M., & Piccolo, S. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.005 · Cited by 1,970 · cited 1×
“YAP can induce the reprogramming of cancer cells into cancer stem cells in some models [88].”
BackgroundKRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733
The role of ROS in tumour development and progression
Cheung, E. C., & Vousden, K. H. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00435-0 · Cited by 1,595
Inflammation meets cancer, with NF-κB as the matchmaker
Ben-Neriah, Y., & Karin, M. (2011) · Nature Immunology · doi:10.1038/ni.2060 · Cited by 1,373 · cited 2×
“These mutations can contribute to elevated levels of the NF-κB signaling which regulates expression of many inflammatory cytokines, including IL-6, IL8 and IL-18 [70].”
Background
Cited by
Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer
Stefanoudakis, D., Frountzas, M., Schizas, D., Michalopoulos, N. V., Drakaki, A., & Toutouzas, K. G. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46040177 · Cited by 110
“…in fl uencing mRNA degradation mechanisms [36]. variants, alter tumor microenvironment, promoting proliferation and chemotherapy resistance [34, Cases with TP53 mutations often co-occur These mutations, particularly gain-of-function (GOF) variants, alter the tumor microenvironment,…”
BackgroundTP53 Mutation-Mediated Immune Evasion in Cancer: Mechanisms and Therapeutic Implications
Wang, C., Tan, J. Y. M., Chitkara, N., & Bhatt, S. (2024) · Cancers · doi:10.3390/cancers16173069 · Cited by 68
“The cGAS-STING pathway is a critical mechanism of the innate immune system that detects cytosolic DNA, a signal often associated with viral infections or cellular damage [14,61].”
BackgroundAkter, K., Gul, K., & Mumtaz, S. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47090716 · Cited by 74
“Extensive research indicates that nonfunctional mutated p53 sig-Curr nificantly contributes to tumor initiation and progression, correlating with poor clinical outcomes, reduced survival rates, unfavorable prognosis, and chemotherapy resistance in oncology patients [80–82].”
Zhang, C.-Y., Liu, S., & Yang, M. J. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i48.6827 · Cited by 40
TP53 to mediate immune escape in tumor microenvironment: an overview of the research progress
Zhu, K., Su, F., Yang, J., Xiao, R., Wu, R.-Y., Cao, M.-Y., Ling, X., & Zhang, T. (2024) · Molecular Biology Reports · doi:10.1007/s11033-023-09097-7 · Cited by 42
I, A. R., Shiu, K., & Khan, K. H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1142838 · Cited by 28
“Interestingly, gain of function (GOF) mutations in TP53 inhibit p73 preventing binding of nuclear factor-Y transcription factor (NFY) which increases gene expression of PDGFR-b that is required for development of the fibrotic PDAC TME (52).”
BackgroundHossen, M. B., Islam, M. A., Reza, M. S., Kibria, M. K., Horaira, M. A., Tuly, K. F., Faruqe, M. O., Kabir, F., & Mollah, M. N. H. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.106411 · Cited by 25
Argentiero, A., Andriano, A., Caradonna, I. C., Martino, G. D., & Desantis, V. (2024) · Cancers · doi:10.3390/cancers16132438 · Cited by 25
“Consequently, the inactivation of wild-type TP53 activity directly affects cell cycle progression, apoptosis, and senescence [13].”
BackgroundMcCubrey, J. A., Abrams, S. L., Follo, M. Y., Manzoli, L., Ratti, S., Martelli, A. M., & Cervello, M. (2022) · Advances in Biological Regulation · doi:10.1016/j.jbior.2022.100917 · Cited by 14
Self-citationChen, Y., Deng, Q., Chen, H., Yang, J., Chen, Z., Li, J., & Fu, Z. (2023) · Scientific Reports · doi:10.1038/s41598-023-43495-y · Cited by 15
“Tumors with high levels of CD8 T cell infiltration in the TME are regarded as immunogenically hot tumors, which respond better to immune checkpoint inhibitors 43 .”
BackgroundInfluentialVerloy, R., Privat‐Maldonado, A., Audenaerde, J. R. M. V., Rovers, S., Zaryouh, H., Waele, J. D., Quatannens, D., Peeters, D. J. E., Roeyen, G., Deben, C., et al. (2025) · Cells · doi:10.3390/cells14060450 · Cited by 12
“SMAD4 is correlated to an increased rate of metastasis and resistance to therapy, and TP53 changes the immune milieu and promotes inflammation, which benefits the tumor [10,11].”
Henderson, E. A., Ivey, A. D., Choi, S. J., Santiago, S. P., McNitt, D. H., Liu, T. W. B., Łukomski, S., & Boone, B. A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1363962 · Cited by 9
Vučinić, D., Bukovica, A. M., Antončić, I., Radojčić, M. K., Lekić, M., & Couñago, F. (2025) · Genes · doi:10.3390/genes16070732 · Cited by 11
“Preclinical models demonstrate that restoration of wild-type TP53 function using MDM2 inhibitors (e.g., nutlin-3a) can reinstate T-cell activity and reduce tumor-promoting inflammation, offering another potential radiosensitization strategy [59].”
Pathway-Specific Genomic Alterations in Pancreatic Cancer Across Populations at Risk
Monge, C., Waldrup, B., Carranza, F., Manjarrez, S., & Velazquez-Villarreal, E. I. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167695 · Cited by 10
“In addition to TP53 mutations, CDKN2A deletions are frequently observed in PC and are associated with aggressive tumor behavior [28,29].”
Revolutionizing pancreatic cancer treatment with CAR-T therapy
Baghel, K., Mehrotra, S., & Prajapati, V. K. (2025) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2024.10.008 · Cited by 9
Safa, A., Vruzhaj, I., Gambirasi, M., & Toffoli, G. (2025) · Cancers · doi:10.3390/cancers17213506 · Cited by 7
Emerging therapeutic advancements in pancreatic cancer: a contemporary review
Malla, M., Sakr, Y., Gupta, G., Akce, M., & El‐Rayes, B. F. (2025) · Discover Oncology · doi:10.1007/s12672-025-03027-8 · Cited by 8
“Hence, major therapeutic strategies targeting p53 can be classified into two categories based on their p53 status either to restore wtp53 functions or eradicate mutp53 [56, 57].”
Molecular Biomarkers for the Diagnosis and Prognostication of Pancreatic Ductal Adenocarcinoma
Sun, J. X., Awad, M. A., Hwang, J., & Villano, A. M. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15060236 · Cited by 7
Salihoğlu, R., Nieves, J., Dandekar, G., Ebert, R., Rudert, M., Dandekar, T., & Bencúrová, E. (2025) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2025.09.028 · Cited by 6
Emerging horizons on molecular and circulating biomarkers in pancreatic adenocarcinoma
Moretti, M., Farina, A., Angeloni, A., & Anastasi, E. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1483306 · Cited by 7
Fang, Y., Tan, C., Zheng, Z., Yang, J., Tang, J., Guo, R., Silli, E. K., Chen, Z., Chen, J., Ge, R., et al. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116849 · Cited by 6
Savsani, K., & Dakshanamurthy, S. (2024) · Diseases · doi:10.3390/diseases12070149 · Cited by 7
“The TP53 gene is mutated in about 50% of PDAC patients [11].”
BackgroundKluz, N., Kraj, L., Chmiel, P., Przybyłkowski, A. M., Wyrwicz, L. S., Stec, R., & Szymański, Ł. (2024) · Cancers · doi:10.3390/cancers16233945 · Cited by 5
“These mutations, particularly gain-of-function variants, alter the tumor microenvironment, promoting tumor proliferation and resistance to chemotherapy [34,35].”
Stefanoudakis, D. (2025) · SynBio · doi:10.3390/synbio3010001 · Cited by 5
“Gain-of-function (GOF) TP53 mutations, in particular, promote tumor proliferation and chemotherapy resistance and often co-occur with KRAS mutations, indicating early KRAS involvement in pancreatic carcinogenesis [11,13].”
Yuan, X., Huang, H., Yu, C., Tang, Z., & Li, Y. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03024-8 · Cited by 5
“By limiting the accumulation of ROS, it affects the oxidative stress response, thereby participating in tumor suppression (Aubrey et al. 2016; McCubrey et al. 2022).”
Keratin 17 modulates the immune topography of pancreatic cancer
Coka, L. D., Horowitz, M., Gonçalves, M. T., Roa‐Peña, L., Leiton, C. V., Hasan, M., Babu, S., Fassler, D., Oentoro, J., Bai, J.-D. K., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05252-1 · Cited by 7
“Several studies have reported that TP53 missense mutations lead to reduce the infiltration of cytotoxic CD8 + T cells and approximately 70% of all PDACs harbor TP53 gene mutations [28, 30, 39].”
BackgroundCHEN, D.-J., & Lai, C. (2023) · Biocell · doi:10.32604/biocell.2023.028883 · Cited by 5
Cai, H., Shen, D., Hu, X., Yin, H., & Yan, Z. (2025) · Toxins · doi:10.3390/toxins17080388 · Cited by 4
“Furthermore, abnormalities in TP53 can modify the tumor microenvironment by impacting inflammatory factors [35,36], aligning with our findings.”
Noncoding Ribonucleic Acids (RNAs) May Improve Response to Immunotherapy in Pancreatic Cancer
Ala, M. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00394 · Cited by 4
Duan, Y., Du, Y., Mu, Y., Gu, Z., & Wang, C. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1096679 · Cited by 5
“…types of cancer, including pancreatic cancer, ovarian cancer, esophageal cancer, colorectal cancer, head and neck cancer, laryngeal cancer and lung cancer (Olivier et al., 2010; Peltonen et al., 2010; Mogi and Kuwano, 2011; Yurgelun et al., 2015; Silwal-Pandit et al., 2017; McCubrey et al., 2022).”
BackgroundFunction and Therapeutic Potential of Non-Coding RNA in Ameloblastoma
Huang, X., Gu, F., Zhao, M., Huang, W., Han, W., Chen, R., & Wang, Y. (2024) · OncoTargets and Therapy · doi:10.2147/ott.s474038 · Cited by 4
“10,11 So far, the exploration of markers and genetic variants has been the focus of molecular research in AB for accurate diagnosis and better prognosis prediction.”
BackgroundWang, B., Zhang, B., & Li, C. (2025) · IET Systems Biology · doi:10.1049/syb2.70035 · Cited by 2
Zhao, Y., Pan, X., Luo, Z., & Liu, Q. (2026) · BMC Biology · doi:10.1186/s12915-026-02613-8 · Cited by 2
“…offering critical insights into tumor heterogeneity and microenvironment dynamics that underlie disease progression and therapeutic resistance [54, 55]. scPASI was further applied to evaluate its capability in identifying cell subpopulations (scPASI + and scPASI − ) directly associated with…”
Singh, N. K., Ahmad, F., & Husain, A. (2026) · Pathology - Research and Practice · doi:10.1016/j.prp.2026.156506 · Cited by 3
Unraveling the therapeutic landscape of miRNAs in pancreatic cancer
El‐Moaty, Z. A., Wasef, M. W., Elsayed, Y. A., Shafiq, A. S., Elnagar, M. A., Mohamed, H. R., Elesawyf, A. E., Mageed, S. S. A., Mohammed, O. A., Abdel‐Reheim, M. A., et al. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04301-w · Cited by 2
“These mutations affect the tumor micro-environment, encouraging development and resistance to treatment, specifically gain-of-function (GOF) variants (McCubrey et al. 2022).”
Current Treatment Methods in Pancreatic Cancer and the Need for Improvement
Banigallapati, S. (2024) · Journal of Student Research · doi:10.47611/jsrhs.v13i4.8357 · Cited by 2
Association of TP53 and EZH2 with salivary adenoid cystic carcinoma
Di, Y., Zhang, H., Zhang, B., & Li, D. (2025) · Journal of Stomatology Oral and Maxillofacial Surgery · doi:10.1016/j.jormas.2025.102526 · Cited by 1
The Multi-Target lncRNA–miRNA–mRNA TRIAD in Pancreatic Cancer Diagnosis and Therapy
Jeong, H.-S., Lee, Y. J., Lee, D. H., Roh, H.-Y., Jeong, G.-R., & Kim, H. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031400 · Cited by 1
Matini, E., Abouelela, E., Ogunbiyi, O., & Suwaidan, A. A. (2026) · Immuno · doi:10.3390/immuno6010015 · Cited by 1
“Mutant TP53 decreases the efficacy of dendritic cells (DCs) and increases interleukin-6 (IL-6) production, thus leading to reduced neoantigen expression and increased metastatic potential, respectively [25].”
Wu, D., Li, Z., Pan, Y., Lai, J., Shi, Y., Xu, X., Tian, Y., Huang, L., & Chen, S. (2026) · Annals of Surgical Oncology · doi:10.1245/s10434-026-20627-y · Cited by 1
Dai, Y., Pan, Y.-T., Lin, D., Chen, X., Zhou, X., & Wang, W. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27216 · Cited by 1
Research of immunotherapy in pancreatic cancer
Li, Z. (2024) · BIO Web of Conferences · doi:10.1051/bioconf/202411102026
“In the later stages of cancer occurrence and development, approximately 75% of patients carry p53 mutations [16, 17].”
BackgroundEnigmatic role of T cells in pancreatic ductal adenocarcinoma: An introspective study
Swetha, C. H., Hemalatha, M., Teja, K. D., & Girish, B. P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23523-8.00001-8
Ai, X. (2025) · Theoretical and Natural Science · doi:10.54254/2753-8818/2025.gu20451
NDRG-1: Pankreas Kanserindeki Rolü ve Potansiyel Etki Mekanizmaları
Raday, S., & Yılmaz, H. (2025) · Haliç Üniversitesi Sağlık Bilimleri Dergisi · doi:10.48124/husagbilder.1640760
Zhao, Z., Zhang, J., Zhang, J., Liu, F., Wang, B., Zhou, Y., Li, X., Li, R., Ma, J., Wu, H., et al. (2025) · Oncology Letters · doi:10.3892/ol.2025.15211 · Cited by 1
“However, mutations in the oncogene KRAS and the tumor suppressor gene tumor protein 53 (TP53) (7,8) lead to excessive connective tissue proliferation, forming a mechanical barrier around tumor cells.”
Chen, Y., Dai, S., Cai, W., Zhao, J., Zhang, F., Cheng, C., & Chen, L. (2025) · Cell Biology and Toxicology · doi:10.1007/s10565-025-10096-6
Mukherjee, A. (2024) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/dz5y-w391
Additional file 1 of Keratin 17 modulates the immune topography of pancreatic cancer
Coka, L. D., Horowitz, M., Gonçalves, M. T., Roa‐Peña, L., Leiton, C. V., Hasan, M., Babu, S., Fassler, D., Oentoro, J., Bai, J.-D. K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26719098
Zhang, S. N., Song, X., Fu, K., & Liu, J. W. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1819664
“” The former likely arises from TP53-driven genomic instability, metabolic stress, and necrotic – fi brotic interplay within the tumor (31), while the latter re fl ects invasive behavior and epithelial – mesenchymal interactions that induce stromal remodeling and in fl ammatory in fi ltration at the…”
Liu, K.-J., Tan, Z., Tang, Y., Lv, Y., & Bu, Y. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08572-6
“Gain-of-function missense mutations in TP53 can exacerbate fibrosis and suppress CD8 + T-cell infiltration, thereby enhancing immune evasion and accelerating disease progression [35, 36].”
Elsherbiny, L. M., Motaal, A. A. A., El‐Askary, H. I., Manie, T., & Youness, R. A. (2026) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-026-10909-z
“Accordingly, the oncogenic lncRNA H19 [49 ] and the tumor suppressor miRNAs; miR-486-5p [50]; miR-194-5p [ 51] and miR-22-3p [52] have been evaluated in MDA-MB-231 cells treated by serial dilutions of 3,5-DCQA.”
The Impact of miR-200s on Ovarian Cancer
Carter, R. J. (2024) · The Atrium (University of Guelph)
Tan, X., Jiang, A., Chen, T., & Ahmed, A. (2026) · Research Square · doi:10.21203/rs.3.rs-11039446/v1
Metadata
- Authors
- McCubrey, J. A., Yang, L. V., Abrams, S. L., Steelman, L. S., Follo, M. Y., Cocco, L., Ratti, S., Martelli, A. M., Augello, G., & Cervello, M.
- Affiliations
- East Carolina University (US)
- University of Bologna (IT)
- Institute for Biomedical Research and Innovation (IT)
- Corresponding author
- McCubrey, James A.
- ORCID
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2022-07-09
- Volume
- 11
- Issue
- 14
- Pages
- 2155
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC9318640
- OpenAlex
- W4285014119
- Cited by
- 49
- References
- 210
- Citations by year
- 2026: 5 · 2025: 20 · 2024: 17 · 2023: 3 · 2022: 4
- FWCI
- 1.34
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- East Carolina University Grant (#111104, #111110-668715-0000)
- Fondazione del Monte di Bologna e Ravenna Research grant (#111104, #111110-668715-0000)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- TP53 mutation, microRNA, pancreatic ductal adenocarcinoma, tumor microenvironment, desmoplasia, immune response, tumor progression, gain-of-function mutations, chemoresistance
- MeSH terms
- Humans, Immunity, Mutation, Pancreatic Neoplasms, Tumor Suppressor Protein p53, Carcinoma, Pancreatic Ductal, MicroRNAs, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.